News

Long delays between symptom onset and diagnosis are common with amyotrophic lateral sclerosis (ALS), and need not be if general practitioners (GPs) were more aware of the disease and its likely “red flags,” a study suggests. Its researchers highlighted specific “flags,” like difficulties with speech or swallowing or muscle…

QurAlis Corporation has licensed preclinical small molecule compounds — designed to treat amyotrophic lateral sclerosis (ALS) — from Eli Lilly and Company, furthering QurAlis’s specialization in ALS treatment development. The investigational molecules are aimed at specifically counteracting a pathological symptom of ALS called excitotoxicity, a process…

Patient dosing has finished in the pivotal Phase 3 trial assessing the safety and efficacy of repeat administrations of NurOwn, a cell-based therapy for people with amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics, the therapy’s developer, announced. The Phase 3 trial (NCT03280056), which enrolled…

Weight loss at the time of diagnosis appears common among people with amyotrophic lateral sclerosis (ALS), regardless of whether they have dysphagia or other bulbar-onset symptoms, a study looking at more than 2,400 patients found. A severe degree of weight loss is associated with a higher risk of death, its…

Scientists have identified molecules that enable them to study and manipulate a specific type of cell present in the central nervous system, called glial cells, at the junctions where nerve cells communicate with muscles. Understanding how these cells operate at such sites, called neuromuscular junctions or synapses, has…

A research project underway at the University of Rhode Island (URI) aims to help people with advanced amyotrophic lateral sclerosis (ALS) and other severely limiting disorders communicate better by interacting with a computer that can translate their thoughts. Among the consequences of motor diseases like ALS is the…

Distinct RNA patterns in a person’s blood may signal the presence of amyotrophic lateral sclerosis (ALS), a study reports. Researchers, led by Majid Hafezparast, PhD, a professor of molecular neuroscience at the University of Sussex in the U.K., discovered that certain types of non-coding RNA (ncRNA), a…